Lyell Immunopharma (LYEL)

• Market cap: $490M
• 1 day: 1.59%
• 5 days: -5.41%
• 1 month: -7.35%
• 3 months: 1.54%
• 6 months: 110.3%
• Year to date: -20.39%
• 1 year: 73.46%
• 5 years: -93.17%
• 10 years: -93.17%
• Sector: Healthcare
• Industry: Biotechnology

About: Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Employees: 300